Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
11:25am, Thursday, 27'th Jun 2024
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
08:51am, Wednesday, 26'th Jun 2024
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral v
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
08:55am, Tuesday, 18'th Jun 2024
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
08:00am, Monday, 17'th Jun 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a p
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
01:27pm, Friday, 14'th Jun 2024
The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif
Outlook Therapeutics: Worth A Good Strong Look After CRL
05:22pm, Thursday, 13'th Jun 2024
Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to con
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
03:21pm, Wednesday, 12'th Jun 2024
SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River (CRL) Partners to Reduce Animal Research Usage
09:16am, Tuesday, 11'th Jun 2024
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces an integrated program, funded by a $1.3 million grant, to develop an in vitro alternative to inhalation toxicology studi
SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
08:00am, Thursday, 06'th Jun 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of a new CRADL® facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.
Charles River Laboratories to Present at William Blair and Jefferies Conferences
08:00am, Monday, 03'rd Jun 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday,
